For example, a bispecific antibody (BsAb) that simultaneously targets both EGFR and programmed cell death protein 1 (PD1), a protein that is involved in immune checkpoint blockade, has been investigated as a novel and promising strategy to effectively treat cancers [50,51]. The gene discussed is EGFR; the disease is cancer.